Global Oncology Academy
The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.
For more information about GOA, visit www.globaloncologyacademy.org.
Episodes 16-30 of 259
Evaluating Axatilimab in Chronic GVHD: How Prior Therapies Impact Outcomes
Project Oncology®Evaluating Axatilimab in Chronic GVHD: How Prior Therapies Impact Outcomes
Evaluating Patient and Clinician-Reported Responses to Axatilimab in cGVHD
Project Oncology®Evaluating Patient and Clinician-Reported Responses to Axatilimab in cGVHD
Advancing Precision Medicine in NSCLC: Real-World Impact of the PREDICT Initiative
Project Oncology®Advancing Precision Medicine in NSCLC: Real-World Impact of the PREDICT Initiative
Impacts of Multidisciplinary Tumor Boards and Surgery Integration on NSCLC Survival
Project Oncology®Impacts of Multidisciplinary Tumor Boards and Surgery Integration on NSCLC Survival
AAT C-Terminal Peptides Show Independent Prognostic Value in Early-Stage NSCLC
Project Oncology®AAT C-Terminal Peptides Show Independent Prognostic Value in Early-Stage NSCLC
Early Liquid Biopsy in Advanced Lung Cancer: Real-World Data Suggest Targeted Gains
Project Oncology®Early Liquid Biopsy in Advanced Lung Cancer: Real-World Data Suggest Targeted Gains
- advertisement
Managing Chronic Graft-Versus-Host Disease with CSF1R Inhibition
Project Oncology®Managing Chronic Graft-Versus-Host Disease with CSF1R Inhibition
Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
Project Oncology®Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role
Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
Project Oncology®Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
Optimizing Treatment Pathways in NSCLC: The Role of the Multidisciplinary Team
Deep Breaths: Updates from CHESTOptimizing Treatment Pathways in NSCLC: The Role of the Multidisciplinary Team
Evolving Strategies in Resectable NSCLC: Insights from ASCO and ASTRO 2025
Deep Breaths: Updates from CHESTEvolving Strategies in Resectable NSCLC: Insights from ASCO and ASTRO 2025
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
Project Oncology®Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
- advertisement
Exploring Elacestrant Combinations for ER+/HER2- mBC: Early Data from ELEVATE
Project Oncology®Exploring Elacestrant Combinations for ER+/HER2- mBC: Early Data from ELEVATE
Elacestrant and Targeted Therapies in Breast Cancer: Preliminary Data From ELECTRA and ELEVATE
Project Oncology®Elacestrant and Targeted Therapies in Breast Cancer: Preliminary Data From ELECTRA and ELEVATE
Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
Project Oncology®Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
